Suppr超能文献

纤溶药物在治疗肺炎旁胸腔积液中的应用

Fibrinolytics in the treatment of parapneumonic effusions.

作者信息

Bouros D, Schiza S, Siafakas N

机构信息

Dept of Pneumonology, Medical School, University of Crete, Greece.

出版信息

Monaldi Arch Chest Dis. 1999 Jun;54(3):258-63.

Abstract

Intrapleural instillation of fibrinolytic agents has been shown, in a number of studies, to be an effective and safe mode of treatment in complicated parapneumonic effusions and empyema, minimizing the need for surgical intervention. Streptokinase and urokinase are the fibrinolytics used, but the technique of instillation is not yet standardized. The usual dose of streptokinase is 250,000 IU, 100,000 IU for urokinase. Fibrinolytics are diluted in 30-100 mL normal saline and the success rate ranges 50-100%, depending on the stage of pleural effusion. Generally, fibrinolytics are more successful if used early in the process of pleural infection (in complicated parapneumonic effusions rather than in empyemas). Adverse reactions are rare, of the allergic type and more frequent for streptokinase. Urokinase is safer but more expensive.

摘要

多项研究表明,在复杂性肺炎旁胸腔积液和脓胸的治疗中,胸膜腔内注入纤溶药物是一种有效且安全的治疗方式,可减少手术干预的需求。使用的纤溶药物是链激酶和尿激酶,但注入技术尚未标准化。链激酶的常用剂量为250,000国际单位,尿激酶为100,000国际单位。纤溶药物用30 - 100毫升生理盐水稀释,成功率在50% - 100%之间,具体取决于胸腔积液的阶段。一般来说,如果在胸膜感染过程早期(在复杂性肺炎旁胸腔积液而非脓胸时)使用纤溶药物,成功率更高。不良反应很少见,多为过敏类型,链激酶更常见。尿激酶更安全但更昂贵。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验